Davide Matino at BIC 2025: Phase 3 Data on Fitelparvovec for Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Updated Ph3 data on gene therapy for haemophilia A with giroctocogene fitelparvovec (AAV6, 3e13 vg/kg in 74 participants), presented by Davide Matino at BIC meeting 2025:
~35% of participants maintained near-normal to normal FVIII activity (40–150%) at 2 years post-infusion
Durability data is impressive: sustained efficacy approaches three years of follow-up, demonstrating the transformative potential of this AAV6 approach
- Slow decline pattern:
– Year 1 mean: 51.7%
– Year 2 mean: 51.9% (stabilization)
– Year 3 mean: 40.7% (median: 38.0%)
Note: Only 8 participants had 3-year follow-up
- Sustained FVIII levels >5% in >80% of participants at 15 and at 24 months
- 98.3% reduction in treated bleeding episodes (4.08 → 0.07 ABR post-infusion)
- Transient FVIII activity >150% in nearly 50%, managed with low-dose prophylactic DOAC in 30%
- One participant developed a thrombotic event (history of thrombosis and risk factors)
- 2 participants resumed FVIII prophylaxis
Generally well-tolerated safety profile with manageable ALT elevations (ALT ↑ in 61%)
High rate of infusion-related reactions (75%), but no discontinuation of study drug administration
One case of new cancer at 35 months (oral SCC, not related to study drug); in total 2 malignancies reported
One case of FVIII inhibitor development (more to follow tomorrow!)
Despite these results, Pfizer has discontinued this program and terminated their collaboration with Sangamo Therapeutics in December 2024”
More from BIC 2025 featured in Hemostasis Today.
-
May 12, 2026, 14:01Moses Wasswa: Tackling Sickle Cell Disease in Uganda
-
May 12, 2026, 13:58Arun Chervu: Most DVT Patients Do Well on Anticoagulation Alone
-
May 12, 2026, 13:49Shashank Joshi: Antiphospholipid Antibodies and Risk of Thrombotic Cardiovascular Events
-
May 12, 2026, 13:44Hayley Evans: Variability in Perioperative TXA Practice Despite Strong Evidence
-
May 12, 2026, 11:13Matteo Foschi: Grateful To Be Selected for The WSO Future Stroke Leaders Programme
-
May 12, 2026, 11:05Omid Seidizadeh: Strategies to Guide The 2nd 100 years of VWD Care and Research
-
May 12, 2026, 11:01Kate Scrivener: The Big Picture of Exercise Trials to Prevent Falls After Stroke
-
May 12, 2026, 10:39Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
-
May 12, 2026, 10:26Fabrice Cognasse: The EFS Is First and Foremost Part of a Medical Discipline – Transfusion